Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia. Show more

Location: 4960 Peachtree Industrial Boulevard, Norcross, GA, 30071, United States | Website: https://galectintherapeutics.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

158.9M

52 Wk Range

$0.73 - $3.90

Previous Close

$2.45

Open

$2.49

Volume

392,073

Day Range

$2.43 - $2.64

Enterprise Value

236.8M

Cash

7.431M

Avg Qtr Burn

-9.338M

Insider Ownership

30.44%

Institutional Own.

15.78%

Qtr Updated

03/31/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Belapectin (GR-MD-02) Details Non-alcoholic steatohepatitis , metabolic dysfunction-associated steatohepatitis	Phase 2/3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Belapectin (GR-MD-02) + keytruda Details Head and neck cancer, Head and neck squamous cell carcinoma	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Belapectin (GR-MD-02) Details Psoriasis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.